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 Supplementary Table 1 
 
Populations contributing to the analysis 
Abbreviations: L1, lineage 1; L2, lineage 2; L3, lineage 3; L4, lineage 4; Susc., susceptible; DR, 
resistant to at least one drug but not MDR-TB/XDR-TB. Notes: *Bangladesh (8), China (1), 
Nepal (4), Pakistan (1), Philippines (4), South Korea (39), Thailand (1), Cameroon (1), Central 
African Republic (1), Equatorial Guinea (1), Guinea (1), Morocco (4), Niger (1), Nigeria (1), 
Democratic Republic of Congo (4), Rwanda (15), Gemany (12), Kazakstan (1), Portugal (1), 
Spain (2), Brazil (7), Colombia (1), Domican Republic (1), Peru (31); ** Malaysia, South Africa, 
and Thailand (96); *** PRJEB10950, PRJEB10385; **** ERP013054, PRJEB10950; ***** 
PRJNA183624, PRJNA235615, PRJEB10385; ****** PRJEB2221, PRJEB5162, PRJEB6273, 
PRJEB6276, PRJEB7281, PRJEB7727, PRJEB9680, PRJNA282721; bolded ENA accession 











Canada 11 0 0 0 11 11 0 0 0 SRA020129 
Brazil 108 0 0 0 108 4 9 85 10 PRJEB10385 
Colombia 15 0 0 0 15 0 0 15 0 PRJEB10385 
Peru 78 0 6 0 72 26 31 18 3 PRJEB10385 
Bulgaria 2 0 0 0 2 0 0 2 0 PRJEB10385 
Germany 20 0 0 0 20 20 0 0 0 ERP006619 
Portugal 183 0 20 1 162 19 71 67 26 ERP002611 
Russia 2 0 2 0 0 1 1 0 0 ERP000192 
China 161 0 122 2 37 44 0 94 23 SRP018402 
Vietnam 43 16 19 0 8 22 6 15 0 PRJEB10385 
India 3 0 0 2 1 1 0 2 0 PRJEB10385 
Pakistan 42 5 0 33 4 5 0 0 37 ERP008770 
Saudi Arabia 74 10 11 18 35 57 6 11 0 *** 
Malawi 1646 264 71 195 1116 1526 112 8 0 ERP000436 
South Africa 594 8 231 15 340 81 131 208 174 **** 
Uganda 45 1 1 13 30 3 2 40 0 ERP000520 
WHO* 138 14 34 4 86 35 51 52 0 ***** 
Mixed** 96 4 38 4 50 96 0 0 0 ERP001037 
UK 3204 295 466 706 1737 2500 343 356 5 ****** 
Total 6465 617 1021 993 3834 4451 763 973 278  
% 100 9.5 15.8 15.4 59.3 68.8 11.8 15.1 4.3  
Supplementary Table 2 
Drug Lineage 1 Lineage 2 Lineage 3 Lineage 4 Total Resistant (%) 
Rifampicin (RIF) 31/616 580/1002 81/992 649/3748 1341 (21.1) 
Isoniazid (INH) 93/615 602/1012 161/992 892/3765 1748 (27.4) 
Ethambutol (EMB) 17/405 366/914 37/844 317/2862 737 (14.7) 
Pyrazinamide (PZA) 20/394 270/666 41/798 222/2360 553 (13.1) 
Streptomycin (STR) 28/234 449/758 47/300 491/2170 1015 (29.3) 
Capreomycin (CAP) 1/19 131/378 10/67 128/687 270 (23.5) 
Amikacin (AMK) 5/19 129/257 28/72 66/553 228 (25.3) 
Kanamycin (KAN) 6/27 139/397 28/72 156/731 329 (26.8) 
Moxifloxacin (MOX) 0/18 67/235 2/40 22/357 91 (14.0) 
Ofloxacin (OFL) 3/23 167/465 5/65 228/849 403 (28.7) 
Ethionamide (ETH) 2/7 108/301 3/36 171/386 284 (38.9) 
Ciprofloxacin (CIP) 5/48 2/24 32/108 23/176 62 (17.4) 
PAS 0/0 7/119 0/0 13/136 20 (7.8) 
D-Cycloserine (CYS) 0/0 39/117 0/0 17/131 56 (22.6) 
       









Susceptible 510 (82.7) 368 (36.0) 815 (82.1) 2758 (71.9) 4451 (68.8) 
DR 78 (12.6) 103 (10.1) 103 (10.4) 479 (12.5) 763 (11.8) 
MDR-TB 23 (3.7) 430 (42.1) 47 (4.7) 473 (12.3) 973 (15.1) 
XDR-TB 6 (1.0) 120 (11.8) 28 (2.8) 124 (3.2) 278 (4.3) 
Total 617 1021 993 3834 6465  
(%) (9.5) (15.8) (15.4) (59.3) (100)  
 
Drugs susceptibility test data (resistant/tested) and the phenotypes considered 
Abbreviations: DR, resistant to at least 1 drug but not MDR-TB/XDR-TB; MDR-TB, multidrug-
resistant tuberculosis; XDR-TB, extensive drug-resistant tuberculosis; PAS Para-aminosalicylic 



























katG S315T 0.4 36.9 71.7 73.4 
rpoB S450L 0.1 12.1 64.2 56.1 
rpsL K43R 0.6 11.5 42.2 23.5 
embB M306V 0.0 6.2 31.2 39.4 
embB M306I 0.2 6.2 17.4 35.2 
Rv1482c-fabG1 C-15T 0.3 21.9 16.9 36.3 
rrs A1401G 0.0 4.4 10.1 72.3 
rrs A514C 0.2 2.4 5.3 27.4 
gyrA A90V 0.0 0.5 4.1 32.1 
gyrA D94G 0.3 4.0 4.5 26.5 
gid L79S 0.0 0.7 2.1 27.5 
rpoB L452P 0.0 1.6 3.2 18.7 
ethA-ethR T-65C 0.0 0.4 4.4 17.8 
Rv1482c-fabG1 T-8A 0.0 0.8 3.5 17.3 
rpoB D435V 0.0 0.4 6.2 14.9 
rpoB D435G 0.0 0.1 0.2 18.5 
ubiA V188A 0.0 0.0 0.2 17.3 
rpoB I1106T 0.0 0.0 0.1 17.3 
inhA S94A 0.0 5.7 4.3 8.6 
Rv1482c-fabG1 G-17T 0.0 1.1 0.9 11.2 
inhA I194T 0.0 2.8 3.1 9.0 
ubiA A249T 0.0 0.1 0.9 10.8 
PPE52-nuoA G-314T 0.0 0.1 1.0 11.2 
eis-Rv2417c C-10T 0.0 2.2 3.4 6.9 
rpsL K88R 0.1 3.7 5.3 1.4 
iniA H42R 0.0 0.1 0.6 10.8 
gyrA D94A 0.0 0.9 2.2 8.5 
alr L113R 0.0 0.3 0.9 9.9 
pncA Q10* 0.0 0.0 0.3 0.0 
embB Q497R 0.0 1.4 5.3 1.8 
rpoB D435Y 0.0 1.1 2.7 5.5 
rpoB H445Y 0.0 1.8 4.3 1.4 
gyrA S91P 0.1 1.4 1.3 6.1 
embC-embA C-12T 0.0 0.1 3.0 2.5 
embB G406A 0.0 0.5 3.1 2.5 
pncA Q10P 0.0 0.0 4.8 1.1 
eis-Rv2417c G-12A 0.0 0.0 4.7 0.7 
embC-embA C-16T 0.0 1.6 2.0 2.9 
embC-embA C-16G 0.0 0.4 1.5 4.0 
rpoB H445D 0.0 1.3 3.9 0.4 
gyrA D94Y 0.0 0.3 1.0 4.4 
thyX-hsdS.1 G-16A 0.0 0.9 2.3 2.2 
rpoB L731P 0.0 2.1 1.3 2.5 
embB G406D 0.0 1.2 2.4 2.2 
pncA V125G 0.0 2.1 1.4 2.6 
embC-embA C-11A 0.0 1.2 0.9 4.0 
katG S315R 0.0 1.1 1.7 2.2 
pncA-Rv2044c T-11C 0.0 0.1 2.7 2.3 
katG S315N 0.0 1.3 1.8 2.2 
gyrA D94N 0.1 0.1 0.5 5.5 
embB M423T 0.0 2.1 1.0 2.5 
gid A80P 0.0 2.1 1.0 3.1 
embC-embA G-43C 0.0 0.3 1.7 1.4 
embB D354A 0.0 0.4 2.3 0.7 
Rv2172c-idsA2 A-65G 0.0 1.2 0.8 3.3 
embC-embA C-12A 0.0 1.2 0.8 3.2 
embB P397T 0.0 1.2 0.8 3.2 
rrs C517T 0.0 0.7 1.9 0.7 
eis-Rv2417c G-14A 0.0 0.1 1.1 2.2 
embB G406S 0.0 0.7 1.9 0.4 
rpoB H445R 0.1 0.1 1.9 0.4 
embB D1024N 0.0 0.4 1.0 2.9 
oxyR’-ahpC G-48A 0.0 0.5 1.0 1.8 
alr M343T 0.0 0.9 0.5 2.5 
rpoB S450W 0.0 0.7 1.8 0.0 
oxyR’-ahpC C-52T 0.1 0.3 1.7 0.4 
rpoB H445L 0.0 0.4 1.2 1.1 
pncA V139M 0.0 0.3 0.4 1.9 
rpoB H445N 0.1 2.5 0.5 0.0 
rpoB L430P 0.1 1.1 1.2 0.0 
embC-embA C-8T 0.0 0.1 0.4 1.8 
rpoB I491F 0.2 2.5 0.8 0.0 
pncA W68* 0.0 0.0 0.1 0.0 
Rv1482c-fabG1 T-8C 0.4 0.4 0.9 0.4 
pncA Q141P 0.0 0.4 1.3 0.4 
gyrA D94H 0.0 0.0 0.4 2.2 
rrs A514T 0.0 1.9 0.2 0.4 
rpoB M434I 0.0 0.0 0.1 0.0 
  
Allele frequency of resistance mutations 
Abbreviations: DR, Resistant to at least 1 drug but not MDR-TB/XDR-TB; MDR-TB, multidrug-
resistant tuberculosis; XDR-TB, extensively drug-resistant tuberculosis; IGR, intergenic region; 





















4 gyrA 7570 X v M or SUS 1.51E-15 0.001 0.005 0.042 0.321 
4 gyrA 7572 X v SUS 8.92E-21 0.001 0.014 0.013 0.061 
2 gyrA 7581 X v MDR 7.99E-06 0.001 0.004 0.019 0.120 
3,4 gyrA 7581 X v SUS 1.17E-21 0.001 0.004 0.019 0.120 
2,3 gyrA 7582 X v M 3.71E-07 0.003 0.050 0.067 0.349 
4 gyrA 7582 X v M or SUS 8.52E-07 0.003 0.050 0.067 0.349 
2 rpoB 760314 M v SUS 4.92E-22 0 0.004 0.006 0 
3 rpoB 761108 X v SUS 3.44E-14 0 0 0.002 0.018 
2-4 rpoB 761109 M or X v SUS, RMP 3.34E-28 0 0.011 0.027 0.055 
3,4 rpoB 761110 X v M, X or M v SUS, RMP 3.35E-85 0 0.007 0.066 0.333 
1,2,4 rpoB 761139 X or M v SUS 3.46E-16 0.001 0.057 0.087 0.018 
1-4 rpoB 761139 M v SUS, RMP 1.61E-97 0.001 0.057 0.087 0.018 
1,2,4 rpoB 761140 M or X v SUS, RMP 2.66E-17 0.001 0.005 0.033 0.014 
1-4 rpoB 761155 M or X v SUS, RMP 1.17E-219 0.001 0.128 0.358 0.439 
2,4 rpoB 761161 M or X v SUS 9.67E-18 0 0.016 0.032 0.187 
4 rpoB 763123 X v M or SUS 1.13E-17 0 0 0.001 0.173 
3 rpoC 764666 X or M v SUS, RMP 3.74E-29 0 0 0.006 0.011 
2 rpoC 764819 M v SUS 3.33E-18 0 0.001 0.011 0 
4 rpoC 766823 X v SUS 1.64E-06 0 0.012 0.008 0.032 
1 rpoC 767123 MDR or XDR v SUS, RMP 3.91E-24 0 0 0.013 0.011 
2-4 rpsL 781687  XDR v SUS, STM 1.65E-45 0.006 0.115 0.422 0.235 
2-4 rpsL 781822 STM 4.16E-10 0.002 0.038 0.060 0.014 
1 rrs 1472358 STM 5.12E-06 0 0.008 0.005 0 
4 rrs 1472359 STM 2.66E-13 0.002 0.043 0.056 0.278 
1,3 rrs 1472359 M or X v SUS 5.71E-18 0.002 0.043 0.056 0.278 
1 rrs 1472362 M or X v SUS, STM 3.52E-71 0 0.007 0.019 0.007 
3 rrs 1472751 X v SUS 2.28E-10 0 0.003 0.004 0.011 
2,4 rrs 1473246 AMK, CAP, KAN 6.68E-42 0 0.044 0.101 0.277 
3 rrs 1473246 STM 3.05E-09 0 0.044 0.101 0.277 
2-4 rrs 1473246 X v SUS or M 7.73E-246 0 0.044 0.101 0.277 
1 pncB1 1499617 PZA 3.20E-06 0 0 0.005 0.004 
1 echA12 1660232 X v M or SUS 3.91E-24 0 0 0.005 0.004 
2 Rv1482c-fabG1 1673425 ETH 1.91E-04 0.003 0.219 0.169 0.363 
1,3,4 Rv1482c-fabG1 1673425 M or X v SUS, INH 4.07E-56 0.003 0.219 0.169 0.363 
4 Rv1482c-fabG1 1673432 X v SUS 2.63E-15 0.004 0.012 0.046 0.183 
4 inhA 1674481 X v SUS 8.54E-46 0 0.057 0.043 0.086 
1,4 inhA 1674782 M or X v SUS 3.91E-24 0 0.028 0.031 0.09 
1-4 katG 2155168 M or X v SUS, INH 3.26E-286 0.004 0.382 0.283 0.266 
4 pncA 2288868 X v SUS, PZA 1.60E-14 0 0.022 0.016 0.026 
1 pncA 2288952 M or X v SUS, PZA 3.91E-24 0 0.003 0.01 0.004 
2 pncA-Rv2044c 2289252 PZA 1.12E-08 0 0.001 0.029 0.027 
4 eis-Rv2417c 2715342 KAN 1.93E-08 0 0.022 0.037 0.069 
2 oxyR'-ahpC 2726141 X v SUS 4.53E-08 0.001 0.004 0.024 0.004 
2 alr 3841083 Cycloserine 1.67E-08 0 0.003 0.009 0.099 
2,4 embC-embA 4243217 X or M v SUS, EMB 2.09E-14 0 0.021 0.043 0.068 
3,4 embC-embA 4243221 X v SUS, EMB 1.70E-32 0 0.013 0.038 0.058 
4 embC-embA 4243222 X v SUS, EMB 2.62E-10 0 0.012 0.011 0.040 
1-4 embB 4247429 M or X v SUS, EMB 1.28E-47 0.001 0.064 0.317 0.401 
1-4 embB 4247431 M or X v SUS, EMB 1.58E-51 0.002 0.062 0.174 0.363 
1 embB 4247574 X or M v SUS, EMB 3.63E-07 0 0.004 0.023 0.007 
4 embB 4247702 X v SUS, EMB 2.62E-08 0 0.012 0.008 0.032 
4 embB 4247729 X or M v SUS, EMB 8.81E-13 0 0.009 0.02 0.004 
2,4 embB 4247730 X v SUS, EMB 3.31E-12 0 0.017 0.055 0.047 
4 embB 4247781 X v SUS 9.20E-10 0 0.021 0.010 0.025 
1,3,4 embB 4248003 M or X v SUS, EMB 1.33E-26 0 0.017 0.057 0.025 
3 embB 4249583 X v SUS, EMB 5.84E-23 0 0.004 0.010 0.029 
4 ubiA 4269271 X v M or SUS 1.01E-16 0 0 0.002 0.173 
3 ethA 4326435 X v SUS 3.44E-14 0 0 0 0.018 
4 ethA-ethR 4327484 X v SUS 9.24E-44 0 0.004 0.044 0.178 
4 ethR 4328127 X v SUS 9.30E-10 0 0.021 0.010 0.025 
4 gid 4407965 X v SUS 6.27E-10 0 0.021 0.010 0.031 
 
Lineage specific SNP associations 
Abbreviations: X, XDR-TB; M, MDR-TB; Susc., Pan susceptible; DR, resistant to at least one 
drug but not MDR-TB/XDR-TB; RIF, rifampicin; INH, isoniazid; ETH, ethionamide; EMB, 




















Supplementary Table 5 
 





Rifampicin rpoB rpoC* < 2.2e-16 
Rifampicin rpoB rpoA* 6.0e-09 
Isoniazid katG ahpC* < 2.2e-16 
Pyrazinamide pncA pncB2 1.4e-13 
Ethambutol embB ubiA < 2.2e-16 
PAS thyA thyX-hsdS.1 < 2.2e-16 
 
 
Detected co-occurrence of mutations at drug resistance associated loci (Fisher exact test 
P<10-8)  
 
Abbreviations: PAS, para-aminosalicylic acid. Note: underlying overall and lineage data are 























Co-occurrence of mutations at drug resistance associated loci with a breakdown by lineage 
Each table contains the number of isolates with and without mutations (‘mutant’ (Mut) & ‘wild type’ 
(WT) respectively) at each pair of drug resistance associated loci effects identified or known 
compensatory effects. ‘Mutant’ refers to isolates with SNP and indel non-synonymous amino acid 
changes. Synonymous amino acid changes and deep phylogenetic mutations were discarded. Cells 
with grey background show statistically significant correlations (Fisher exact test P<0.02), i.e. pairs of 
genes frequently mutated in the same isolates, whereas white background indicates lack of statistical 
significance. This analysis points to putative epistatic and compensatory relationships. 
  
  rpoB (81-bp rifampicin resistance-determining region) 
  Overall Lineage 1 Lineage 2 Lineage 3 Lineage 4 
  WT Mut. WT Mut. WT Mut. WT Mut. WT Mut. 
rpoC WT 4964 873 557 30 417 322 888 49 3102 472 Mut. 138 477 15 15 25 251 28 28 70 183 
rpoA WT 5060 1308 564 45 439 553 915 76 3142 634 Mut. 43 42 8 0 3 20 1 1 31 21 
  katG 
  Overall Lineage 1 Lineage 2 Lineage 3 Lineage 4 
  WT Mut. WT Mut. WT Mut. WT Mut. WT Mut. 
ahpC 
promoter 
WT 4959 1390 554 58 472 525 826 156 3107 651 
Mut. 35 62 4 0 5 16 5 5 21 41 
  pncA 
  Overall Lineage 1 Lineage 2 Lineage 3 Lineage 4 
  WT Mut. WT Mut. WT Mut. WT Mut. WT Mut. 
pncB2 WT 5608 599 560 23 704 280 953 18 3391 278 Mut. 116 59 24 0 9 0 13 0 70 59 
pncB1 WT 5576 647 528 15 701 280 927 17 3420 335 Mut. 147 11 58 8 12 0 37 1 40 2 
  ethA 
  Overall Lineage 1 Lineage 2 Lineage 3 Lineage 4 
  WT Mut. WT Mut. WT Mut. WT Mut. WT Mut. 
pyrG WT 5922 285 541 33 914 59 933 43 3534 150 Mut. 143 15 38 1 7 2 14 0 84 12 
Rv0565c WT 5969 292 562 34 914 56 915 42 3578 160 Mut. 90 8 17 0 6 5 30 1 37 2 
  embB 
  Overall Lineage 1 Lineage 2 Lineage 3 Lineage 4 
  WT Mut. WT Mut. WT Mut. WT Mut. WT Mut. 
ubiA WT 5033 1281 502 91 489 475 886 97 3156 618 Mut. 45 104 21 3 3 54 9 1 12 46 
  thyA 
  Overall Lineage 1 Lineage 2 Lineage 3 Lineage 4 
  WT Mut. WT Mut. WT Mut. WT Mut. WT Mut. 
thyX-
hsdS1 
WT 6332 36 600 4 982 10 973 14 3777 8 
Mut. 67 21 13 0 14 14 6 0 34 7 





















3840259 Y388D 0.0009 0 -3.369 -3.384 -3.737 2.682 -2.819 
3840258 Y388C 0.0002 0 -1.889 -1.704 -1.938 2.682 -2.489 
3840393 M343T_B 0.0031 0.0358 -2.118 -2.085 0.368 3.636 -0.195 
3840708 S238L 0.0002 0 0.611 1.192 0.69 4.246 -0.551 
3840952 K157E 0.0003 0 -1.483 -1.455 -1.841 4.474 -0.075 
3840636 P262Q 0.0012 0 -2.015 -2.069 0.279 4.987 -0.863 
3840717 S235W 0.0002 0 -0.807 -1.460 0.706 5.212 -0.588 
3840402 R340L_B 0.0003 0 -0.57 0.616 0.160 5.389 -0.629 
3840643 L260V 0.0002 0 -1.244 -1.554 -2.467 6.992 -0.419 
3840639 S261N 0.0002 0 -1.443 -1.606 -0.482 7.116 -0.248 
3841083 L113R 0.0057 0.4461 -0.961 -0.956 -1.721 8.477 -0.423 
 
Protein structural modelling of alr reveals low frequency mutations conferring higher 
instability  
We applied four measures to quantify the enthalpic effects (the change in Gibbs free energy 
- ∆∆G) of point mutations on overall protein structure stability (mCSM and DUET), protein-
protein interactions (mCSM-PPI) and interaction with substrate/drug (mCSM-Lig). Negative 
values indicate a destabilising effect, with the most destabilising highlighted in grey, and 
positive values indicating an increase in stability. The geometrical distance from the mutation 
to the drug binding position is also provided. The mutation that was statistically significant 
with the largest resistance frequency (L113R) has a relatively large destabilising effect both 
on the overall protein structure and in drug binding, yet it is the furthest from the site of drug 
interaction. Abbreviations: CYS, D-cycloscerine. Notes: * protein stability; ** drug binding, 


















Supplementary Table 8 
 
Gene-based small insertion and deletion (indel) associations 
Abbreviations: Susc., susceptible; MDR-TB, multidrug-resistant tuberculosis; XDR-TB, 


































MDR-TB vs. Susc. embCAB promoter 72.29 6 1 1-2 8.34E-09 
MDR-TB vs. Susc. pncA 44.72 25 1 1-15 2.09E-08 
MDR-TB vs. Susc. rpoB 2.27 7 6 3-9 3.91E-03 
XDR-TB vs. Susc. ethA 25.89 38 1 1-10 9.76E-79 
XDR-TB vs. Susc. pncA 44.72 25 1 1-15 1.20E-23 
XDR-TB vs. Susc. rpoB 2.27 7 6 3-9 4.63E-14 
XDR-TB vs. Susc. embCAB promoter 72.29 6 1 1-2 6.93E-07 
XDR- vs. MDR-TB pncA 44.72 25 1 1-15 3.80E-06 
XDR- vs. MDR-TB ald 10.77 12 1 1-5 4.85E-04 
XDR- vs. MDR-TB rrs 2.61 4 1 1-1 2.71E-03 
Isoniazid katG 5.40 12 1.5 1-12 2.82E-05 
Rifampicin rpoB 2.27 7 6 3-9 1.25E-10 
Ethionamide ethA 25.89 38 1 1-10 7.22E-09 
Capreomycin tlyA 3.73 3 2 2-10 1.21E-12 
Capreomycin rrs 2.61 4 1 1-1 2.37E-10 
Streptomycin gid 35.66 24 1 1-14 1.45E-09 
Pyrazinamide pncA 44.72 25 1 1-15 5.27E-38 
Cycloserine ald 10.77 12 1 1-5 5.35E-03 
Kanamycin rrs 2.61 4 1 1-1 9.29E-05 
Supplementary Table 9 







dfrA/thyA 5 PAS 1 3 6,396 2,825-7,912 
pncA 12 PZA 1 3 1,402 446-4,670 
ethA/ethR 7 ETH 3 3 3,667 1,513-5,271 
katG 3 INH 3 0 5,729 4,789-7,608 
 
Large deletions in candidate drug resistance regions 
Abbreviations: DR, resistant to at least one drug but not MDR/XDR-TB; XDR-TB, extensively 
drug-resistance tuberculosis; PAS, para-aminosalicylic acid; ETH, ethionamide; PZA, 
pyrazinamide; INH, isoniazid. 
